ESSA Pharma Inc. financial data

Symbol
EPIX on Nasdaq
Industry
Pharmaceutical Preparations
Location
Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2024 - Aug 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.8K % -36.3%
Debt-to-equity 2.83 % +64.5%
Return On Equity -20.2 % -16.9%
Return On Assets -19.6 % -15.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.4M shares +0.61%
Common Stock, Shares, Outstanding 44.4M shares +0.63%
Entity Public Float 78.8M USD -53%
Common Stock, Value, Issued 280M USD +0.58%
Weighted Average Number of Shares Outstanding, Basic 44.4M shares +0.62%
Weighted Average Number of Shares Outstanding, Diluted 44.4M shares +0.62%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 22.2M USD +8.79%
General and Administrative Expense 11.6M USD -0.25%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.23M USD +0.89%
Income Tax Expense (Benefit) 1.6K USD
Net Income (Loss) Attributable to Parent -27.7M USD -0.89%
Earnings Per Share, Basic -0.62 USD/shares 0%
Earnings Per Share, Diluted -0.62 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 86M USD +124%
Assets, Current 132M USD -13.8%
Operating Lease, Right-of-Use Asset 318K USD +234%
Assets 133M USD -13.7%
Accounts Payable, Current 1.91M USD -6.95%
Accrued Liabilities, Current 869K USD +13%
Liabilities, Current 3.58M USD +4.91%
Operating Lease, Liability, Noncurrent 230K USD
Liabilities 3.8M USD +11.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.1M USD +1.03%
Retained Earnings (Accumulated Deficit) -202M USD -15.9%
Stockholders' Equity Attributable to Parent 129M USD -14.2%
Liabilities and Equity 133M USD -13.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.79M USD -55.1%
Net Cash Provided by (Used in) Financing Activities 197K USD +1156%
Net Cash Provided by (Used in) Investing Activities 8.23M USD
Common Stock, Shares, Issued 44.4M shares +0.63%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.64M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 86M USD +124%
Deferred Tax Assets, Valuation Allowance 45.2M USD +12.5%
Deferred Tax Assets, Gross 45.2M USD +12.5%
Operating Lease, Liability 342K USD +207%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27.6M USD -0.83%
Lessee, Operating Lease, Liability, to be Paid 400K USD
Operating Lease, Liability, Current 112K USD +1.04%
Lessee, Operating Lease, Liability, to be Paid, Year Two 133K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 118K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 57.6K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 137K USD
Deferred Tax Assets, Operating Loss Carryforwards 43.7M USD +16%
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.7K USD
Operating Lease, Payments 34.6K USD +7%
Additional Paid in Capital 52.9M USD +9.66%
Deferred Tax Assets, Net of Valuation Allowance 0 USD